Members of the TGFb superfamily of signalling molecules play important roles in mesendoderm induction and dorsoventral patterning of the vertebrate embryo. We cloned three intracellular mediators of TGFb signalling, smad1, 2 and 5, from the zebra®sh. The three smad genes are expressed ubiquitously at the onset of gastrulation. The pattern of expression becomes progressively restricted during somitogenesis suggesting that at later stages not only the distribution of the TGFb signal but also that of the intracellular smad signal transducer determine the regionally restricted effects of TGFb signalling. Forced expression of smad1 leads to an expansion of blood cells resembling the phenotype of moderately ventralized zebra®sh mutants. In contrast to Smad1, neither Smad2 nor Smad5 caused a detectable effect when expressed as full-length molecules suggesting that these latter two Smads are more dependent on activation by the cognate TGFb ligands. Nterminal truncated Smad2 dorsalized embryos, in agreement with a role downstream of dorsalizing TGFb members such as Nodals. In contrast to the C-terminal MH2 domain of Smad2, the C-terminal region of Smad1 and Smad5 lead to pleiotropic effects in embryos giving rize to both dorsalized and ventralized characteristics in injected embryos. Analysis of truncated zebra®sh Smad1 in Xenopus embryos supports the notion that the C-terminal domain of smad1 is both a hypomorph and antimorph which can act as activator or inhibitor depending on the region of expression in the embryo. These results indicate a speci®c function of the MH1 domain of Smad1 and 5 for activity of the molecules. q
Introduction
Members of the TGFb family of signalling factors play crucial roles during homeostasis and development (Massague, 1990; Kingsley, 1994; Hogan, 1996) . Bone morphogenetic proteins (BMP) which form a sub-group within the TGFb superfamily are required for mesoderm formation during vertebrate gastrulation. Mouse embryos lacking BMP4 activity have severe defects in mesoderm formation (Winnier et al., 1995) . BMP2, 4 and 7 are inducers of ventral mesodermal and ectodermal derivatives in amphibians and zebra®sh (Dale et al., 1992; Fainsod et al., 1994; Hammerschmidt et al., 1996; Kishimoto et al., 1997) . swirl 2/2 homozygous zebra®sh mutants lacking BMP2b function exhibit an expansion of dorsal structures such as notochord, somites and neuroectoderm on the expense of ventral structures such as epidermis and blood (Hammerschmidt et al., 1996; Mullins et al., 1996; Kishimoto et al., 1997; Nguyen et al., 1998) . Nodal and nodal related TGFb like factors are also required for mesoderm development in both mouse and zebrafrsh (Zhou et al., 1993; Conlon et al., 1994; Feldman et al., 1998; Rebagliati et al., 1998b; Sampath et al., 1998) Compound zebra®sh mutants carrying mutations in the two nodal related factors cyclops (cyc) and squint (sqt) lack most of the mesendoderm (Feldman et al., 1998) . When ectopically expressed, nodals induce dorsal structures such as axial mesoderm and somites (Jones et al., 1995; Smith et al., 1995; Toyama et al., 1995; Rebagliati et al., 1998a) . TGFb and related ligands with the exception of GDNF bind to heterodimers of transmembrane receptors composed of type I and type II receptor serine/threonine kinases (reviewed in (Massague, 1998; Wrana, 1998) . Binding of the ligand leads to activation of the Smad signal transduction pathway by speci®c phosphorylation of Smad molecules (reviewed in Baker and Harland, 1997; Heldin et al., 1997; Massague et al., 1997; Hoodless and Wrana, 1998) . Smads form a novel family of signal transducers which share a domain structure which is conserved from the nematode C. elegans to humans. The amino terminal MH1 domain (Mad homology 1) is separated from the carboxyterminal MH2 (MAD Homology 2) domain by a less strongly conserved linker regions. Smad molecules can be subdivided into distinct groups according to functional criteria. The so-called pathway restricted smads act downstream of speci®c receptors. Smad1, 5, 8 and 9 were shown to act downstream of BMP receptor kinases Liu et al., 1996; Kretzschmar et al., 1997b; Macias-Silva et al., 1998; Nakayama et al., 1998) while Smad2 and 3 are activated by Activin and TGFb receptors Graff et al., 1996) . The amino-terminal MH1 domain acts as a repressor of the activity of the C-terminal MH2 domain in Smad2 and 4 Liu et al., 1997) . Receptor kinase mediated phosphorylation at a conserved SSXS motif at the carboxy terminus releases the MH2 domain from inhibition by the amino terminal MH1 domain and allows the pathway restricted Smads to heterodimerize with the common partner Smad4 (Lagna et al., 1996; Zhang et al., 1997; Shioda et al., 1998) . In addition, inhibitory Smads such as Smad6 and 7 have been identi®ed that inhibit the interaction of the pathway restricted smads with either the type 1 receptor kinase or with Smad4 (Hayashi et al., 1997; Imamura et al., 1997; Nakao et al., 1997; Hata et al., 1998) .
Upon phosphorylation and heterodimerization with Smad4, pathway restricted Smads either translocate to the nucleus and act themselves as sequence speci®c DNA binding factors or recruit other DNA binding factors which target the Smad complex to speci®c responsive genes (reviewed in Derynck et al., 1998) . Mad, the Drosophila homologue of vertebrate Smad1, contains a DNA binding domain in its MH1 domain (Kim et al., 1997) . Similarly Smad3/Smad4 complexes have sequence speci®c DNA binding activity on their own but can also form higher order complexes with other transcription factors (Dennler et al., 1998; Labbe et al., 1998; Vindevoghel et al., 1998; Zawel et al., 1998) . Speci®c DNA binding activity has not been reported for full length Smad2; a splice variant, however, appears to bind DNA (Yagi et al., 1999) . As in the case of Smad3, sequence speci®c activation of genes is mediated by the interaction of the Smad2/Smad4 complex with other factors such as the winged-helix DNA binding factors Fast-1 and Fast-2 (Chen et al., 1996; Chen et al., 1997; Liu et al., 1997; Labbe et al., 1998) .
Distinct tissues along the dorsoventral axis of the gastrula in Xenopus as well as zebra®sh appear to be speci®ed by gradients of inducers. The ventral region of the gastrula is the source of BMPs which induce at high concentrations the ventral most tissues such as blood and ventral tail ®n and at lower concentrations progressively more lateral tissues (Dosch et al., 1997; Wilson et al., 1997; Nguyen et al., 1998) . Similarly, Activin A which mimics the activity of nodal and nodal related factors in that it induces dorsal mesoderm was proposed to act as a morphogen (Green, 1990) . These observations suggest that the level of Smad activation is critical in shaping the dorsoventral axis (Dosch et al., 1997; Neave et al., 1997; Wilson et al., 1997) . Intracellular antagonism between dorsalizing Activin/BVg1 and ventralizing BMP-2/4 signalling may be mediated by the competition of pathway restricted Smads for the common partner Smad4 (Candia et al., 1997) .
Several mutations were identi®ed in zebra®sh embryos which cause alterations along the dorsoventral axis. Mutations in swirl, snailhouse, and somitobun cause an expansion of dorsal structures on the expense of ventral (Mullins et al., 1996) . Conversely, mutations in chordino, mercedes and ogon lead to an expansion in ventral structures (Hammerschmidt et al., 1996; Mullins et al., 1996; Solnica-Krezel et al., 1996) . We report here the cloning and expression of three pathway restricted smads, 1, 2 and 5, from zebra®sh. To compare the activity of these molecules with the mutant phenotypes, we characterized the activity of wild type and amino-terminally truncated variants. We show that full-length Smad1 ventralizes embryos in a manner similar to mutations in chordino or mercedes. In contrast, neither Smad2 nor Smad5 caused phenotypes when expressed as full length molecules. Deletion of the amino-terminal MH1 domain generated a constitutively active form of Smad2 resulting in strong dorsalized phenotype, reminiscent of dorsalized mutants. We furthermore show that deletion of the amino-terminus of Smad1 and Smad5 leads to loss of speci®city in that misexpressing embryos show both ventralized as well as dorsalized features. Evidence is provided that amino-terminally truncated Smad1 can act as pathway speci®c inhibitor as well as activator suggesting that the amino terminus of Smad1 is required for normal biological function.
Results

Cloning and expression of zebra®sh smad1, smad2 and smad5
Smad homologous sequences were isolated by RT PCR with RNA from 18 h old embryos employing oligonucleotide primers complementary to regions conserved between Drosophila Mad Sekelsky et al., 1995) . C. elegans sma-2 (Savage et al., 1996) and human smad1 . Two different fragments were isolated resembling mammalian smad1 and smad2 most closely. Ampli®ed fragments were subsequently used as probes to obtain full-length cDNAs from a gastrula stage library (Rebagliati et al., 1998a) . smad5 was isolated by re-screening the library under low stringency conditions. Sequence comparison with human, mouse and Xenopus Smad proteins strongly suggests that the clones obtained are the ®sh orthologues of mammalian smad1, smad2, and smad5, respectively (Fig. 1) . Designation of smad5 was based on the stronger homology to mammalian Smad5 (92%) than to zebra®sh Smad1 (89%) and on the signi®cantly higher degree of homology to mammalian and chick Smad5 in the less conserved linker region (data not shown).
To assess the pattern of expression, digoxygenin-labelled antisense RNAs were generated from subclones and mRNA expression was analysed by in situ hybridization on wholemount embryos between beginning of gastrulation (50% epiboly) to end of somitogenesis. Expression of smad1 becomes weakly detectable throughout the blastoderm cap at 50% epiboly. Stronger smad1 expression was observed in single deep cells of unknown fate ( Fig. 2A) . At the 10-somite stage, high levels of smad1 mRNA are present in the developing eye (Fig. 2B,C) , in mesenchymal/neural crest cells lateral to the head (Fig. 2C , arrowheads) and the somites (Fig. 2D ). Expression persists in the eyes at 26 h of development (Fig. 2E ). Strong expression is present in the trigeminal, acoustic/anterior lateral line and posterior lateral line ganglia (Fig. 2F, arrowheads) . Also within the diencephalon individual cells or small groups of cells express smad1 at higher levels ( Fig. 2E and data not shown). More posteriorly, expression remained detectable in the somites of the anterior tail and in the haemangiogenic region at the 26h stage (Fig. 2G) .
smad2 is strongly expressed throughout the entire blastoderm at the 50% epiboly stage (Fig. 3A) with higher expression in randomly scattered individual blastomeres (Fig. 3A) . At the 10-somite stage, expression was detected throughout the body axis although absolute mRNA levels increased in the trunk and tail (Fig. 3B) . At 26 h, smad2 expression was lower in the hindbrain in comparison to the anterior brain ( Fig. 3C ). High expression was found in head mesenchymal neural crest cells posterior to the eyes (Fig. 3C, arrowheads) . In the trunk and tail, smad2 mRNA was expressed in the endoderm, haemangiogenic region and very weakly in the spinal cord (Fig. 3D) .
Both smad2 and smad5 expression were detected during cleavage stages suggesting that smad2 and 5 are maternal transcripts. RNase protection analysis of total RNA from cleavage stage embryos supports this notion (data not shown). Like smad2, smad5 mRNA is expressed ubiquitously in the early gastrula (Fig. 4A ) and early somitogenesis stage embryos (Fig. 4B) . At 26h of development, smad5 is still broadly expressed in the head even though, as in the case of the other two smad genes, the absolute levels of expression vary regionally (Fig. 4C) . In the trunk, expression is detectable in the dorsal neural tube with single cells expressing higher levels (Fig. 4D) . Expression is also strongly detectable in the forming gut.
Ectopic expression of full length smad1 ventralizes zebra®sh embryos
Misexpression of smads leads to respeci®cation of the dorsoventral axis of Xenopus embryos Thomsen, 1996; Suzuki et al., 1997; Wilson et al., 1997) . To investigate whether the zebra®sh Smad proteins have similar activities in the zebra®sh embryo, full length cDNAs of zebra®sh smad1, smad2 and smad5 were cloned in-frame downstream of 6 myc epitopes in the expression plasmid pCS2mt (Turner and Weintraub, 1994) . Synthetic RNAs were injected into 1±2-cell stage zebra®sh embryos. Only smad1 injected embryos showed an effect. Sixty percent of embryos (Table 1 ) displayed an expansion of blood cells (Fig. 5C ,D) and extra tail ®ns (Fig. 5F ). Expression of the ventrally expressed gata-2 (Detrich et al., 1995) is upregulated and expanded dorsally in smad1 injected 80% epiboly stage embryos ( Fig. 5H ), while expression on the ventral side of uninjected controls stained in parallel is barely detectable (Fig. 5G ). These are characteristics of moderately ventralized zebra®sh embryos (Hammerschmidt et al., 1996; Mullins et al., 1996; Nguyen et al., 1998) . Blocking BMP signalling by expression of a dominantnegative BMP type I receptor (dnBMPR) (Graff et al., 1994; Maeno et al., 1994) transformed embryos (n 71; 29.5%) at the early somitogenesis stage from a round shape into a rugby ball shape reminiscent of the BMP2b mutant swirl (Fig. 5I ) (Hammerschmidt et al., 1996; Mullins et al., 1996; Kishimoto et al., 1997; Nguyen et al., 1998) When smad1 mRNA was injected together with the dnBMPR, the normal round shape was rescued in all embryos (n 80, Fig. 5J ,K). At 24 h of development dnBMPR injected embryos were characterized by the loss of the yolk extension, and blood progenitors, truncated and/ or curly up bent tail and occasionally a secondary posterior embryonic axis (Hammerschmidt et al., 1996; Neave et al., 1997) and data not shown). In embryos co-injected with dnBMPR and smad1 mRNA the dorsalized characteristics were reduced and ventralized features were present in a signi®cant proportion of the embryos (Table 1) . These results are in agreement with an action of Smad1 downstream of the BMP receptor in injected embryos and is consistent with the notion that Smad1 acts in the ventralizing BMP signalling pathway in the zebra®sh embryo.
In contrast to smad1, neither smad2 nor smad5 mRNA even when injected at a concentration of 1 mg/ml showed any morphological alterations in injected embryos (Table 1 and data not shown). Levels of expressed Smad1, 2 and 5 proteins in injected embryos were comparable (data not shown) as assessed by immunohistochemistry with monoclonal antibody 9E10 directed against the myc epitope (Evan et al., 1985) . The 6 myc epitopes in the fusion proteins may affect the function of the protein (Ferreiro et al., 1998) . To exclude this possibility, the myc epitopes were replaced by a single¯ag-tag which has been utilized in several other studies of Smad function (e.g. Hoodless et Percent sequence identity between two sequences was determined with Best®t programme of the GCG package. smad1, 3, 4 and 5 are human sequences whereas smad2 is the mouse gene (accession numbers V54826, AB604922, AF645438, V73825 and V60530, respectively). Macias-Silva et al., 1996; Labbe et al., 1998) . Thē ag-tagged version of Smad2 like myc-tagged Smad2 did not cause an effect in injected embryos while¯ag-Smad1 ventralized embryos in a similar fashion as the myc-tagged version of Smad1 (data not shown). These data suggest that Smad2 and 5 are more stringently controlled than Smad1.
Deletion of the amino terminal domain renders Smad2 constitutively active and dorsalizes zebra®sh embryos
The amino-terminal MH1 domain of smad proteins acts as repressor that inhibits the association with Smad4 and transcriptional activity Liu et al., 1996; Hata et al., 1997) . The requirement for activation by the cognate receptor can be by-passed by deletion of the amino-terminal MH1 domain Liu et al., 1996) . A putative constitutively active variant of Smad2 was generated by deleting the amino terminus from amino acid 1±241 to assess whether its activity could be rendered dominant active in the zebra®sh embryo.
The deletion construct smad2D -241 caused strong dorsalized phenotypes when injected into 1±2-cell stage embryos (Table 1, Fig. 6 ). These embryos resemble nodal injected embryos (Toyama et al., 1995; Erter et al., 1998; Rebagliati et al., 1998a) . As in mutant embryos with a dorsalized phenotype (Mullins et al., 1996) , the yolk extension of the trunk is reduced and frequently posterior trunk and tail is curled up or missing entirely ( Fig. 6A,B; see Fig. 5A ,B for comparison with uninjected control embryo). Expression of dorsal markers such as sonic hedgehog (shh), (Krauss et al., 1993; Roelink et al., 1994) , axial (HNF3b ), (Strahle et al., 1993) and forkhead3 (fkh3), Odenthal and Nu Èsslein-Volhard, 1998) are expanded in injected embryos in comparison to uninjected controls (Fig. 6C,D and data not shown). However, unlike embryos in which the BMP signalling pathway is impaired (Fig. 5I) , smad2 mRNA injected embryos frequently show ectopic patches of expression of the dorsal mesodermal markers shh and axial (HNF3b ) (Fig. 6D and data not shown) . Thus, deletion of the amino-terminal MH1 and linker region of Smad2 results in a constitutively active molecule which promotes differentiation of dorsal tissues in zebra®sh embryos as in Xenopus.
Deletion of the amino-terminus of Smad1 and Smad5 results in loss of biological speci®city
To assess the effect of an amino-terminal deletion on Smad 1 and 5 activity, analogous deletion constructs of smad1 and 5 were cloned. Amino-terminally truncated smad1D 1-239 produced an increase in blood cells (Table  1 , Fig. 7A and data not shown) as seen with embryos injected with full-length smad1 mRNA. However, a large proportion of embryos showed also a range of dorsalized characteristics like loss of ventral tail ®n, reduction of yolk extension and posterior truncations (Fig. 7B±D) , similar to those observed with dnBMPR injected embryos (Hammerschmidt et al., 1996; Neave et al., 1997) or swirl mutants (Mullins et al., 1996) . Even though the frequency of these dorsal features increased when higher concentrations of truncated smad1 mRNA were injected, already at the lowest concentrations (25 ng/ml) a signi®cant proportion of embryos displayed a dorsal phenotype (Table 1) . We also found embryos which combined both dorsalized and ventralized features such as loss of ventral tail ®n together with an increased number of blood cells (Fig. 7B) . Thus, Smad1 appears to lose speci®c biological activity when the MH1 and linker domain has been deleted. Similar results were obtained with the amino-terminally truncated smad5D 1-241 mRNA (Table 1 and data not shown).
Amino-terminally truncated Smad1 causes a dorsalized phenotype when expressed in ventral blastomeres of Xenopus embryos
Several possibilities exist to explain this pleiotropy of the amino-terminally truncated Smad1 and 5. One explanation could be that the carboxy-terminal domain of Smad1 and 5 mimic the activity of Smad2. We stained smad1D 1-239 injected embryos at the three somite stage with the axial (HNF3b) probe. Forty-®ve embryos out of 113 showed the rugby-ball shape characteristic of dorsalized embryos at this stage. In contrast to smad2D 1-241 injected embryos, however, expression of axial (HNF3b ) was relatively unaffected by Smad1D1-239 (Fig. 7G,H) . In this respect, smad1D1-239 injected embryos resemble embryos expressing the dnBMPR (compare with Fig. 5I ). At the same time the somite marker a1-tropomyosin (Ohara et al., 1989 ) is expanded in Smad1D 1-239 injected dorsalized embryos a Dorsalized and ventralized phenotypes were scored at 24 h for the presence of characteristic malformations observed in the dorsalized mutants (Mullins et al., 1996) and ventralized mutants (Hammerschmidt et al., 1996) respectively. while the ventral marker gatal (Detrich et al., 1995) is reduced (data not shown). On the basis of the different effect of Smad1D 1-239 on axial markers to that of smad2D 1-241 the dorsalizing effects of smad1D 1-239 is likely due to dominant negative properties of the truncated molecule. The absolute levels as well as the distribution of the injected mutant proteins in the embryo may explain the pleiotropic effect. To address these possibilities, full length zebra®sh smad1 and smad1D 1-239 mRNA were injected into Xenopus embryos. In contrast to zebra®sh embryos, injection into speci®c blastomeres of the Xenopus embryo allows one to target expression to the ventral or dorsal side of the embryo. Injection of full length smad1 mRNA (500 pg) in dorsal blastomeres resulted in embryos (42%; n 50) which lacked anterior structures such as forebrain, eyes and cement gland while tail development appeared to be enhanced (Fig. 8B) . Injection into ventral blastomeres did not cause a phenotype (n 20) (Fig. 8A) . Embryos (55%; n 40) in which smad1D 1-239 (750 pg) had been injected into dorsal blastomeres, were weakly ventralized (Fig. 8D) ; the size of the eyes was reduced and the brain was smaller. These results suggest that the amino terminally truncated Smad1D1-239 has ventralizing activity but that this activity is weaker than that of wildtype Smad1. When smad1D 1-239 was expressed in ventral blastomeres of Xenopus embryos, however, a large proportion of embryos (70%, n 50) developed dorsalized features (Fig. 8C) ; while the head looked normal, the trunk was shorter and the tail failed to elongate normally. These results suggest that truncated Smad1D1-239 interferes with development of ventral structures when expressed in ventral blastomeres of Xenopus embryos. The truncated molecule has, however, also retained some activating functions as suggested by the weak ventralization of embryos when expressed in dorsal blastomeres.
The Xvent-2B promoter is repressed in ventral and induced in dorsal blastomeres by amino-terminally truncated smad1
The Xvent-2B gene is expressed strongly on the ventral and ventrolateral regions of the Xenopus gastrula (Onichtchouk et al., 1996; Rastegar et al., 1999) . Overexpression of BMP4 or smad1 leads to up-regulation of Xvent-2B expression. Activation of Xvent2-B by BMP4 does not require protein synthesis suggesting that Xvent-2B is a direct target of Smads. This stimulation by BMP4 and Smad1 is mediated by a 2371 bp promoter region of the Xvent-2B gene (Rastegar et al., 1999) . To characterize the activity of Smad1 variants further we tested their effect on the activity of the -371Xvent-2B promoter. The construct -371Xvent-2B::luc which contains the 2371 bp Xvent-2B promoter upstream of a luciferase reporter gene was injected into ventral or dorsal blastomeres alone or together with smad1D 1-239 or full length smad1 mRNA. Luciferase activity was measured in extracts prepared from pools of 10±20 injected embryos. Whereas co-injection of full length smad1 with the reporter construct in ventral blastomeres resulted in a moderate increase in luciferase activity, coexpression of smadD 1-239 resulted in down-regulation of luciferase activity (Fig. 9A) . In contrast, coinjection of either full length smad1 or truncated smadD 1-239 in dorsal blastomeres led to up-regulation of the -371Xvent-2B promoter (Fig. 9B) . These results are in line with the notion that smad1D 1-239 acts as an inhibitor of BMP signals in ventral and as an activator in dorsal blastomeres. These results underscore a requirement of the amino-terminus for full Smad1 function. The pleiotropic effects observed in smad1D 1-239 injected zebra®sh embryos are thus likely the result of both weak activation function and dominant negative activity which are dependent on the position of expression within the embryo.
Discussion
We report here the cloning of three smad cDNAs from zebra®sh which are highly related to mammalian smad1, smad2 and smad5. The high sequence similarity even in regions outside of the highly conserved MH1 and MH2 domains strongly supports the notion that the three zebra®sh genes encode the orthologues of mammalian smad1, 2, and 5. Smad2 and 5 are expressed ubiquitously in the late blastula and early blastula stages. At these stages only weak ubiquitous expression of smad1 was detected with higher levels of expression in individual blastoderm cells of unde- (Fig. 5I) or chordin injected embryos (data not shown), is not found in embryos injected with full length smad1. Expression of axl remains relatively unaffected in all injected embryos. Orientation of the embryos in (A±D) is anterior to the left dorsal up, in (E±H) dorsal view anterior up. ®ned fate. The ubiquitous expression suggests that expression of upstream signalling components such as TGFb ligands and receptors are crucial determinants of the target cell responses during these early stages. While smad2 and 5 are expressed almost uniformly throughout the developing body axis of 10-somite stage embryos, levels of smad1 expression varied regionally at this stage. High level smad1 expression was detected in the eyes, the somites and cells lateral to the brain. By the end of somitogenesis at 24h of development, also expression of smad2 and smad5 has become regionally restricted. This suggests speci®c functions in expressing cells and furthermore that cell responses at these later stages of development are not only determined by the distribution of ligands and receptors but also by expression of a particular smad. Given the lack of placodally derived head ganglia in the BMP2b mutant swirl (Mullins et al., 1996) , expression of smad1 in head ganglia suggests a role of smad1 downstream of BMP2b in speci®-cation of these structures (Nguyen et al., 1998) . Also expression of smad1 and smad5 in the spinal cord is intriguing in view of the proposed role of BMPs in patterning of dorsal neurons (Liem et al., 1995) .
The expression pattern of the three smad genes is in agreement with a function during dorsoventral speci®cation of the zebra®sh gastrula. Indeed, expression of full length smad1 results in an increase in ventral tissues such as blood and ventral tail ®n. This phenotype is reminiscent of that of moderately ventralized embryos such as chordino mutants, in which the dorsal BMP antagonist Chordin is mutated . Even at very high concentrations of injected smad1 RNA we were, however, not able to induce strongly ventralized embryos which can be obtained for example by overexpression of BMP2b or a constitutively active BMP type 1 receptor (Kishimoto et al., 1997) . The moderate ventralization effect of Smad1 may re¯ect that overexpression of full length Smad1 does not mimic ef®-ciently the activity of endogenous Smad1 phosphorylated by ligand bound BMP receptors. smad5 transcripts are much more abundantly expressed in the gastrula in comparison to smad1. Therefore Smad1 may not be suf®cient by itself and other molecules such as Smad5 may play the pivotal role during gastrulation. In support, it was reported recently, that an antimorphic mutation in smad5 is responsible for the dorsalized phenotype of somitabun mutants (Hild et al., 1999) .
We were unable to cause any effect in zebra®sh embryos by overexpressing smad5 or smad2 despite a high level of expression in injected embryos. This inertia of zebra®sh embryos to respond to smad2 and smad5 overexpression is not only in contrast to zebra®sh smad1 but also to reported results from overexpression studies employing full length smad2 and 5 in Xenopus embryos Suzuki et al., 1997) . One explanation for these results in zebra®sh embryos could be that we do not reach the threshold concentration at which Smad2 and Smad5 become independent from activation by cognate receptors. In comparison to Smad1, the activity of Smad2 and 5 appears to be more stringently regulated in the zebra®sh embryo.
In contrast to full-length smad2, expression of an aminoterminally truncated version of smad2 results in embryos which are strongly dorsalized reminiscent of swirl mutant embryos which carry mutations in BMP2b or embryos which misexpressed inhibitors of BMPs such as chordin, noggin or dnBMPR (Hammerschmidt et al., 1996; Kishimoto et al., 1997; Nguyen et al., 1998) . These inhibitors of the BMP pathway do not induce ectopic expression of axial mesodermal markers such as shh and axial (HNF3b ) however, but result merely in a broadening of the axis. Ectopic expression of nodal and activins or expression of the constitutively active TGF type 1 receptor TARAM-A in the zebra®sh embryo cause effects on development similar to expression of the truncated smad2 (Jones et al., 1995; Toyama et al., 1995; Renucci et al., 1996; Rebagliati et al., 1998a) . Misexpression of truncated smad2 mRNA rescued the nodal related cyclops mutant (F.M., P.B. and U.S., unpublished) and a similarly truncated Xenopus homologue of smad2 rescued the phenotype of one eye pinhead which has been identi®ed as a co-factor in Nodal signalling (Gritsman et al., 1999; F.M. and U.S., unpublished) . Given the evidence that Activin type 1 receptors phosphorylate Smad2 (Macias-Silva et al., 1996) , it is likely that constitutively active Smad2 mimics the activity of Nodal and Activins. According to this notion the primary effect of truncated Smad2 would be an expansion of dorsal mesoderm which would lead to reduction of ventral structures indirectly by the increased secretion of BMP inhibitors such as Chordin and Noggin.
In contrast to full length Smad1 which resulted in clear ventralization of embryos, expression of amino-terminally truncated smad1 or smad5 lead to both dorsalized and ventralized features in zebra®sh embryos. When injected into dorsal blastomeres of Xenopus embryos the ventralizing activity of truncated Smad1 is lower than that of the fulllength molecule; embryos injected with truncated smad1 developed small eyes and cement glands while injection of full length smad1 RNA abolished development of the anterior brain, eyes and cement gland. Whereas the truncated Smad1 had weak ventralizing effects when injected into dorsal blastomeres, it led to dorsalization of Xenopus embryos when injected into ventral blastomeres suggesting that the truncation resulted in a dominant negative acting molecule in ventral blastomeres. In agreement, Smad1D1-239 did not lead to ectopic shh expression in dorsalized zebra®sh embryos; instead smad1D 1-239 injected embryos resembled embryos in which BMP signalling was blocked by expression of the dominant negative BMP type 1 receptor. These results suggest that the amino terminus is required for speci®c activity of Smad1 and that the effect of truncated Smad1 depends on the environment in which it is expressed.
The linker region of human Smad1 is a target of negative regulation by tyrosine kinase signalling pathways (Kretzschmar et al., 1997a) . Deletion variants of zebra®sh smad1 and 5 in which only the MH1 domains were deleted and the linker regions were retained, mediate similar pleiotropic effects as smad1 and 5 variants in which both MH1 and linker region have been deleted (F. M., P.B. and U.S., unpublished). This suggests that deletion of the linker region is not responsible for the loss of speci®city.
From experiments in Xenopus and mammalian cell systems it has been suggested that the amino terminal MH1 domain of Smads functions as a repressor of the transactivator activity of the MH2 domain Liu et al., 1996; Hata et al., 1997; Meersseman et al., 1997) . The C-terminal domain of MusMLP a smad1 homolog from Xenopus was shown to retain ventralizing activity when injected into the equatorial region of 4-cell stage embryos (Meersseman et al., 1997) . In contrast, our data show a requirement of the MH1 region for full biological activity of zebra®sh Smad1. In Drosophila Mad, the homologue of vertebrate Smad1 and 5, the MH1 domain was shown to contain a sequence speci®c DNA binding activity (Kim et al., 1997) . Even though it has so far not been Fig. 9 . N-terminal truncated Smad1 can activate as well as inhibit the activity of the Xvent-2B promoter. The -371Xvent-2B::luc reporter construct (20 pg) was injected alone or coinjected with the indicated mRNA either into ventral or dorsal blastomeres of 4-cell stage embryos. Luciferase activity was normalized to that measured in embryos injected with the reporter construct alone and the results of co-injection were expressed as the mean^SD of triplicates.
demonstrated that the MH1 domain of vertebrate Smad1 has DNA binding activity, the high sequence conservation between the MH1 region of Drosophila Mad and vertebrate Smad1 suggests a similar function. The dominant negative activity of truncated Smad1 may thus be due to loss of sequence speci®c DNA binding activity. The different cell types induced by BMPs in the embryo appear to require distinct concentrations of BMPs (Dosch et al., 1997; Neave et al., 1997; Wilson et al., 1997) . As Smad molecules form homo-and heteromeric complexes, it may be that truncated Smad1 with its lower activity may impede the function of full length, BMP-activated, endogenous Smads and that the degree of interference with a particular cellular response to BMP signalling depends on the level of Smad activation required for the response. On the other hand, in cells which were not exposed to or exposed to low levels of BMP signals, the weak activation function of truncated Smad1 may trigger ventralization or synergize with low levels of endogenous smads. We propose that truncated zebra®sh Smad1 acts as both a hypomorph and antimorph depending on the site of expression in the embryo.
Experimental procedures
Fish stocks, embryo production
The wild type zebra®sh line wtOX is derived from ®sh purchased from the Gold®sh Bowl, Oxford, UK and has been bred for several years in the laboratory. Fish were bred and raised as described.
Cloning of smad1, smad2 and smad5
RT PCR cloning employed degenerate primers designed to the conserved peptide sequences PHVIYC and FNNQEFA on cDNA prepared from total RNA of 18 h old zebra®sh embryos. Primers included a BamHI and EcoRI site at the 5 H ends of primers, respectively. Ampli®-cation conditions, after an initial denaturation at 958C for 5 mm, were: 40 cycles of denaturation at 958C for 1 min, annealling at 428C for 1 min and extension at 728C for 1 min followed by a ®nal extension of 10 min at the end of the last cycle. The resulting ampli®ed fragments were subcloned into the EcoRI and BamHI sites of pBSIIKS (Stratagene) and sequenced. Subsequent screening of a cDNA library (Rebagliati et al., 1998a) was carried out using the PCR fragments as probe. The low stringency screening and washing conditions to obtain smad5 are described. (Sambrook et al., 1989) . Plasmid based clones were generated by in vivo excision (Stratagene). All other manipulations were carried out essentially as described (Sambrook et al., 1989) .
Plasmid construction and RNA injection
Full length or N-terminal deleted coding regions were ampli®ed using Pfu polymerase (Stratagene) and subcloned into the expression vectors pCS2, pCS2MT (Turner and Weintraub, 1994) and pCS containing a¯ag epitope tag. The PCR generated constructs were veri®ed by sequencing to exclude the introduction of errors during ampli®cation. The pCS2MT:smad constructs contain the smad coding regions fused in-frame downstream of six copies of an epitope from the cMYC protein that are recognized by monoclonal antibody 9E10 (Evan et al., 1985) .
All smad expression constructs were linearized using NotI prior to transcription. Capped RNA was made using an SP6 transcription kit (Ambion) following the manufacturer's instructions. The integrity of synthetic RNA was assessed on agarose gels and the RNAs were diluted to a ®nal concentration of 200 mg/ml RNA (unless otherwise stated) and 0.2% phenol red immediately prior to injection. Injection was carried out using a gas driven microinjector (Eppendorf).
Xenopus embryos and microinjections
Xenopus laevis embryos were obtained by arti®cial fertilization, de-jellied in 2% cysteine hydrochloride in 0.1£ MBSH (pH 7.5). For injections, embryos were placed into 4% Ficoll in 1£ MBSH. The -371Xvent-2B::luc reporter construct (Rastegar et al., 1999 ) was injected at 20 pg/blastomere either into the dorsal or ventral blastomeres of fourcell stage embryo. When indicated, RNA was coinjected into individual blastomeres. Injected embryos were collected at stage 11 and deep frozen in liquid nitrogen.
Preparation of embryo extracts and luciferase assay
Whole cell extracts were made on ice by homogenization in 30 ml/embryo lysis buffer. After 10 mm on ice and centrifugation for 5 min at 20 000 £ g at 48C, the resulting supernatant was used for the luciferase assay. Ninety microlitres of embryo extract and 30 ml luciferase assay substrate were used for each reaction. Analysis of luciferase activity was carried out with a Lumat LB 9507 (Berthold) for 2 s at room temperature.
In situ hybridization and immunohistochemistry
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